Skip to main content

Research Repository

Advanced Search

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?

Smith, Laura; Qutob, Omar; Watson, Mark B.; Beavis, Andrew W.; Potts, Donna; Welham, Kevin J.; Garimella, Veerabhadram; Lind, Michael J.; Drew, Philip J.; Cawkwell, Lynn

Authors

Laura Smith

Omar Qutob

Mark B. Watson

Andrew W. Beavis

Donna Potts

Kevin J. Welham

Veerabhadram Garimella

Profile image of Michael Lind

Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Philip J. Drew

Lynn Cawkwell



Abstract

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitivities were examined using a clonogenic survival assay. It was revealed that each cell line differed in their response to radiotherapy. These parental breast cancer cell lines were used to establish novel derivatives (MCF7RR, MDA-MB-231RR, and T47DRR) displaying significant resistance to ionizing radiation. Derivative cells were compared with parental cells to identify putative biomarkers associated with the radioresistant phenotype. To identify these biomarkers, complementary proteomic screening approaches were exploited encompassing two-dimensional gel electrophoresis in combination with mass spectrometry, liquid chromatography coupled with tandem mass spectrometry and quantitative proteomics using iTRAQ technology. RESULTS: A large number of potential biomarkers were identified, and several of these were confirmed using Western blot analysis. In particular, a decrease in the expression of the 26S proteasome was found in all radioresistant derivatives when compared with the respective parent cells. Decreased expression of this target was also found to be associated with radioresistant laryngeal tumors (P=.05) in a small pilot immunohistochemical study. CONCLUSIONS: These findings suggest that the 26S proteasome may provide a general predictive biomarker for radiotherapy outcome.

Citation

Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., Garimella, V., Lind, M. J., Drew, P. J., & Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

Journal Article Type Article
Acceptance Date Jul 21, 2009
Online Publication Date Mar 4, 2014
Publication Date 2009-11
Publicly Available Date Jun 26, 2018
Journal NEOPLASIA
Print ISSN 1522-8002
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 11
Issue 11
Pages 1194-1207
DOI https://doi.org/10.1593/neo.09902
Keywords Cancer Research
Public URL https://hull-repository.worktribe.com/output/391308

Files

Article (1.5 Mb)
PDF

Copyright Statement
Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)






You might also like



Downloadable Citations